Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Aksana Jones"'
Autor:
Aksana Jones, Jay Saini, Belinda Kriel, Laura E. Via, Yin Cai, Devon Allies, Debra Hanna, David Hermann, Andre G. Loxton, Gerhard Walzl, Andreas H. Diacon, Klaus Romero, Ryo Higashiyama, Yongge Liu, Alexander Berg
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-18 (2022)
Abstract Background Despite the high global disease burden of tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb) infection, novel treatments remain an urgent medical need. Development efforts continue to be hampered by the reli
Externí odkaz:
https://doaj.org/article/1c33dd8c2a7d407eb03ee7e006988320
Publikováno v:
Pharmaceutics, Vol 13, Iss 6, p 785 (2021)
Fremanezumab, a fully humanized IgG2Δa/kappa monoclonal antibody, selectively targets the calcitonin-gene-related peptide (CGRP) and prevents it from binding to the CGRP receptor. The safety, tolerability, pharmacokinetics (PK), and efficacy of frem
Externí odkaz:
https://doaj.org/article/c1a782b80316404998e3feabfe0ff830
Autor:
Aksana, Jones, Jay, Saini, Belinda, Kriel, Laura E, Via, Yin, Cai, Devon, Allies, Debra, Hanna, David, Hermann, Andre G, Loxton, Gerhard, Walzl, Andreas H, Diacon, Klaus, Romero, Ryo, Higashiyama, Yongge, Liu, Alexander, Berg
Publikováno v:
BMC Infectious Diseases
Background Despite the high global disease burden of tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb) infection, novel treatments remain an urgent medical need. Development efforts continue to be hampered by the reliance on c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68fe2fea8140864ac3efa8f32d9ffffb
http://hdl.handle.net/11427/36368
http://hdl.handle.net/11427/36368
Autor:
Andrijana Radivojevic, Pippa S. Loupe, Michael Brennan, Xiaoping Ning, Michael Gillespie, Orit Cohen-Barak, Andrew H. Ahn, Yoel Kessler, Aksana Jones, Michele Rasamoelisolo, Laura Rabinovich-Guilatt, Jill Fiedler-Kelly, Dikla Gutman, Micha Levi, Hussein Hallak
Publikováno v:
Cephalalgia : an international journal of headache. 41(10)
Background Potential fremanezumab doses for pediatric patients were evaluated using pharmacokinetic modeling and simulation. An open-label phase 1 pharmacokinetic and safety study was conducted in pediatric patients with migraine. This study’s resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52808ded1741d75d6d3addb117322f06
https://pubmed.ncbi.nlm.nih.gov/34000848
https://pubmed.ncbi.nlm.nih.gov/34000848
Publikováno v:
Pharmaceutics
Volume 13
Issue 6
Pharmaceutics, Vol 13, Iss 785, p 785 (2021)
Volume 13
Issue 6
Pharmaceutics, Vol 13, Iss 785, p 785 (2021)
Fremanezumab, a fully humanized IgG2Δa/kappa monoclonal antibody, selectively targets the calcitonin-gene-related peptide (CGRP) and prevents it from binding to the CGRP receptor. The safety, tolerability, pharmacokinetics (PK), and efficacy of frem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff38d9a603a94045c83d27d044421a73
http://europepmc.org/articles/PMC8225049
http://europepmc.org/articles/PMC8225049